Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 16

Results For "damage"

176 News Found

Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn
Biotech | December 22, 2021

Novartis to acquire Gyroscope Therapeutics for up to US $ 1.5 bn

Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with Geographic atrophy


U.S. FDA approves Bristol Myers Squibb’s Orencia
Drug Approval | December 16, 2021

U.S. FDA approves Bristol Myers Squibb’s Orencia

Orencia is the first FDA-approved therapy to prevent acute graft versus host disease following hematopoietic stem cell transplant


Kaka-Ba hospital surgeons perform surgery to correct spine disorder
Hospitals | December 13, 2021

Kaka-Ba hospital surgeons perform surgery to correct spine disorder

Scoliosis is a disorder of the spine, and its surgeries are generally done only in large hospitals in big cities.


Apollo Health Ventures closes US $ 180 million fund
Startup | December 05, 2021

Apollo Health Ventures closes US $ 180 million fund

The fund aims at investing in companies that extends human healthspan


Aster Volunteers offer free diabetes screening in India and UAE
Events | December 03, 2021

Aster Volunteers offer free diabetes screening in India and UAE

In 2019, diabetes was the ninth leading cause of death with an estimated 1.5 million deaths directly caused by diabetes, as per WHO


Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate
Biotech | November 24, 2021

Arrowhead Pharmaceuticals enters agreement with GSK to develop NASH drug candidate

Arrowhead to receive US $ 120 million upfront payment for Phase 1/2 program for NASH and is eligible to receive potential milestone payments and royalties on commercial sales


Amneal gets approval for Difluprednate ophthalmic emulsion
Drug Approval | November 22, 2021

Amneal gets approval for Difluprednate ophthalmic emulsion

The company is moving towards complex and more differentiated products


Merck showcases potential for several cancers, MS and lupus
News | November 22, 2021

Merck showcases potential for several cancers, MS and lupus

Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline


Junk food and low physical activity leading to diabetes: ASSOCHAM report
News | November 15, 2021

Junk food and low physical activity leading to diabetes: ASSOCHAM report

Diabetes has the highest prevalence and comorbidities among all NCD’s in India and it is mostly found among people in the south and east India


LifeCell Diagnostics expands newborn screening portfolio
Clinical Trials | November 11, 2021

LifeCell Diagnostics expands newborn screening portfolio

LSDCheck is CE-IVD approved LCMSMS-based testing kit for LSD in newborns